# Dani Bach

> Dani Bach is a Series A investor at IP Group (Zürich) backing Life Science and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [IP Group](https://shizune.co/investors/profile/ip-group-plc)
- Location: Zürich, Switzerland
- Total investments: 3
- Last investment: Aug 2024
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/danibach/
- X (Twitter): http://twitter.com/dani_at_aravis
- Website: https://x.com/dani_at_aravis

Dani Bach is an Associate in the life sciences team, having joined the firm in 2007.Dani's areas of interest range from metabolic diseases to virology and prior to joining Index, Dani was conducting research at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human immunodeficiency virus(HIV) and the human immune system.Dani holds a Master in Start-up Business Administration and a PhD in Molecular Biology from the Universitat de Barcelona.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 1 | 33% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 33% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vandria | Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $10.1M | Series A | Aug 21, 2024 |  |
| Vandria | Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $20.6M | Series A | Dec 14, 2023 |  |
| Cytoki Pharma | Cytoki Pharma is a biotechnology company that specializes in developing novel medicines for diseases with a significant unmet medical need with a focus on serious diseases caused by epithelial injury. | $45M | Series A | May 04, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 1 deal together
- [Hevolution Foundation](https://shizune.co/investors/profile/hevolution) — VC Fund, 1 deal together
- [Lundbeckfonden Emerge](https://shizune.co/investors/profile/lundbeckfonden-emerge) — VC Fund, 1 deal together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 1 deal together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 1 deal together

## About IP Group

VC Fund · London, United Kingdom

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

5 contacts available at IP Group.

| Name | Title | Profile |
| --- | --- | --- |
| Ben Murphey | Investment Director | https://shizune.co/investors/profile/ben-murphey-ea6e |
| Dani Bach | Partner, Life Sciences | https://shizune.co/investors/profile/dani-bach |
| Greg Smith | Chief Financial Officer | https://shizune.co/investors/profile/greg-smith-3 |
| Jamie Vollbracht | Partner, Cleantech | https://shizune.co/investors/profile/jamie-vollbracht |
| Manjari Chandran-Ramesh | Investment Director | https://shizune.co/investors/profile/manjari-chandran-ramesh |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Dani Bach invest in?

Dani Bach invests primarily in Life Science, Biotechnology and Manufacturing startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dani Bach last invest?

The most recent investment recorded for Dani Bach closed in Aug 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co